background-image
Abbreviations:

4-1BB, tumor necrosis factor receptor superfamily member 9; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor from the tumor necrosis factor family; BAK, Bcl-2 homologous antagonist killer; BAX, Bcl-2-associated X protein; BCL-2, B-cell lymphoma 2; BCMA, B-cell maturation antigen; BCR, B-cell receptor; BH, Bcl-2 homology domain; BiTE, Bispecific T-cell Engager; C5, complement component 5; CD, cluster of differentiation; CIT, chemotherapy-induced thrombocytopenia; CLDN18.2, Claudin-18 isoform 2; DARPin, designed ankyrin repeat proteins; DLBCL, diffuse large B-cell lymphoma; DLL3, delta-like protein 3; EGFR, epidermal growth factor receptor; EGFRvIII, epidermal growth factor receptor variant III; Fab, fragment antigen-binding; FAP, fibroblast activation protein; Fc, fragment crystallizable; FLT3, fms-like tyrosine kinase 3; GEJ, gastroesophageal junction; GM-CSF, granulocyte-macrophage colony-stimulating factor; GvHD, graft versus host disease; HCC, hepatocellular carcinoma; HLE, half-life extended; IL-2R, interleukin 2 receptor; IL-21R, interleukin 21 receptor; IL-2Rα, interleukin 2 receptor alpha; KRAS, Kirsten rat sarcoma; MAC, membrane attack complex; MCL-1, myeloid cell leukemia-1; mCRPC, metastatic castration-resistant prostate cancer; MetMel, metastatic melanoma; MM, multiple myeloma; MOA, mechanism of action; MUC17, mucin 17; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; PNH, paroxysmal nocturnal hemoglobinuria; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; RAS, rat sarcoma; R/R, relapsed or refractory; SCLC, small cell lung cancer; STEAP1, six-transmembrane epithelial antigen of prostate 1; TPO, thrombopoietin; TPO-R, thrombopoietin receptor; Treg, regulatory T cell.

Amgen Oncology
Pipeline

Select a button below to learn more

SOLID MALIGNANCIES

MALIGNANCIES

TARGETS

HEMATOLOGIC DISEASES

DISEASES

TARGETS

PIPELINE

BITE® PLATFORM

BIOSIMILARS

MODALITIES

PD-1

Programmed cell death protein 1 (PD-1) is a protein expressed on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells that helps regulate the body's immune response.1,2 PD-1 is not expressed on naive T cells, and its expression is induced when T cells are activated.2 Known as a “checkpoint protein”, PD-1 binds to its ligands, PD-L1 and PD-L2. PD-1 is expressed on a number of cells, including normal and malignant cells to deactivate the T cell, reduce cytokine production, and reduce proliferation of T cells.1,3 This balance is critical to prevent T cells from attacking normal cells in the body.3

IL-21R, interleukin 21 receptor; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2.

References
1. Chen DS, et al. Clin Cancer Res. 2012;18:6580-6587. 2. Keir ME, et al. Annu Rev Immunol. 2008;26:677-704. 3. American Cancer Society. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed 9/10/20. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04362748. Accessed 9/10/20.
Molecule
Modality4
Target4
Areas of Investigation5
AMG 256
Target4
PD-1
Areas of Investigation5
Molecule
Modality4
Target4
Areas of Investigation4
AMG 404
Target4
PD-1
Areas of Investigation4

IL-21R, interleukin 21 receptor; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2.

References
1. Chen DS, et al. Clin Cancer Res. 2012;18:6580-6587. 2. Keir ME, et al. Annu Rev Immunol. 2008;26:677-704. 3. American Cancer Society. https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed 9/10/20. 4. Amgen Pipeline. https://www.amgenpipeline.com. Accessed 9/10/20. 5. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT04362748. Accessed 9/10/20.

This website may not be accessible on your mobile device; if so, please view on your desktop or tablet.